The Safety and Effectiveness of 935U83 in HIV-Infected Patients
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To assess the safety, tolerance, and steady-state pharmacokinetics of multiple oral doses of
935U83 administered to patients with HIV infection. To obtain preliminary evidence of
antiretroviral activity of 935U83. To prospectively evaluate the emergence of in vitro drug
resistance. To determine the effects of 935U83 dosing on CD4+ cell counts.